Journal
AGING-US
Volume 13, Issue 17, Pages 21268-21282Publisher
IMPACT JOURNALS LLC
Keywords
glioblastoma; chemo-resistance; temozolomide; mitochondrial metabolism; cyclooxygenase-2
Categories
Funding
- Third Affiliated Hospital of Guangzhou Medical University
Ask authors/readers for more resources
Celecoxib has shown to enhance the sensitivity of GBM cells to TMZ in chemotherapy by inhibiting cell proliferation, increasing apoptosis, and autophagy. The potential molecular mechanisms are related to mitochondrial metabolism and respiratory chain inhibition.
Temozolomide (TMZ) is used for the treatment of high-grade gliomas. Acquired chemoresistance is a serious limitation to the therapy with more than 90% of recurrent gliomas showing little response to a second line of chemotherapy. Therefore, it is necessary to explore an alternative strategy to enhance the sensitivity of glioblastoma (GBM) to TMZ in neuro-oncology. Celecoxib is well known and widely used in anti-inflammatory and analgesic. Cyclooxygenase-2 (COX-2) expression has been linked to the prognosis, angiogenesis, and radiation sensitivity of many malignancies such as primitive neuroectodermal tumor and advanced melanoma. The objective of this study was to explore the chemotherapy-sensitizing effect of celecoxib on TMZ in GBM cells and its potential mechanisms. From the study, we found that the combination therapy (TMZ 250uM+celecoxib 30uM) showed excellent inhibitory effect to the GBM, the LN229 and LN18, which were the TMZ resistant GBM cell lines. Our data suggest that the combination therapy may inhibits cell proliferation, increases apoptosis, and increases the autophagy on LN229 and LN18. The potential molecular mechanisms were related to mitochondrial metabolism and respiratory chain inhibition.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available